. 2022 Oct 21;18(6):2136912. doi: 10.1080/21645515.2022.2136912

Table 2.

Seroprotection rate at week 4 (mITT population).

	HepB-CpG		HepB-Eng		HepB-AS04		Difference in SPRs (HepB-CpG – HepB-Eng) (95% CI)^a	Difference in SPRs (HepB-CpG – HepB-AS04) (95% CI)^a	Difference in SPRs (HepB-Eng – HepB-AS04) (95% CI)^a
Visit	Number (n/N) of patients	SPR (95% CI)^a	Number (n/N) of patients	SPR (95% CI)^a	Number (n/N) of patients	SPR (95% CI)^a	Difference in SPRs (HepB-CpG – HepB-Eng) (95% CI)^a	Difference in SPRs (HepB-CpG – HepB-AS04) (95% CI)^a	Difference in SPRs (HepB-Eng – HepB-AS04) (95% CI)^a
Week 4	28/53	52.8% (38.6, 66.7)	15/46	32.6% (19.5, 48.0)	22/51	43.1% (29.3, 57.8)	20.2%^b (0.5, 38.3)	9.7%^c (–9.5, 28.2)	–10.5% (–29.1, 8.9)

anti-HBs, antibody to hepatitis B surface antigen; CI, confidence interval; mITT, modified intent-to-treat population; SPR, seroprotection rate.

^aExact binomial 95% CI (2-sided) for the percentage of patients.

^bStatistically significant difference because lower bound of the 95% CI is >0%.

^cNon-inferiority met because lower bound of the 95% CI is greater than –10%.